GO
Loading...

AstraZeneca PLC

More

  • LONDON, July 30- AstraZeneca took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion to acquire the rights to lung drugs developed by Spain's Almirall.

  • LONDON, July 30- AstraZeneca took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion to acquire the rights to lung drugs developed by Spain's Almirall.

  • July 29- Pfizer Inc, which in May abandoned its $118 billion bid to buy AstraZeneca Plc, on Tuesday left investors guessing whether it would renew its pursuit of its British rival, but said it was considering other deals. Under UK takeover rules, AstraZeneca can attempt to re-engage with Pfizer in August, and Pfizer can make another run at AstraZeneca in November.

  • UPDATE 1-Pfizer beats forecasts as oncology drugs grow Tuesday, 29 Jul 2014 | 7:51 AM ET

    July 29- Pfizer Inc, which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter revenue, helped by growing demand for its cancer medicines.

  • Pfizer's 2Q profit sinks 79 pct but tops forecasts Tuesday, 29 Jul 2014 | 7:37 AM ET

    Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a $10 billion- plus gain from a business spinoff.

  • Merck 2Q profit more than doubles Tuesday, 29 Jul 2014 | 7:28 AM ET

    The maker of popular Type 2 diabetes pill Januvia said Tuesday that net income increased to $2 billion, or 68 cents per share, from $906 million, or 30 cents per share, in the same quarter a year earlier.

  • Pfizer beats forecasts as oncology drugs grow Tuesday, 29 Jul 2014 | 7:28 AM ET

    July 29- Pfizer Inc, which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.

  • BEIJING, July 28- Microsoft Corp appears to be the latest U.S. company targeted by China for anti-trust investigation after government officials paid sudden visits to the software firm's Chinese offices on Monday.

  • Pfizer's need for deal looms with earnings report Monday, 28 Jul 2014 | 7:12 AM ET

    Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.

  • NEW YORK, July 28- Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.

  • Virus drugmaker fights pediatricians' new advice Monday, 28 Jul 2014 | 12:01 AM ET

    CHICAGO— A costly drug given mostly to premature babies is at the center of a clash between the manufacturer and the nation's leading pediatrician's group, which recommends scaling back use of the medicine.

  • Summer's busiest week for markets is here Friday, 25 Jul 2014 | 6:10 PM ET
    Traders work on the floor of the New York Stock Exchange (NYSE) on Friday.

    A crush of big cap earnings and arguably the most important economic reports until September make next week the busiest of the summer for markets.

  • Obama, Dems holding tax reform hostage: Norquist Friday, 25 Jul 2014 | 9:12 AM ET
    Grover Norquist, president of Americans for Tax Reform

    There's been "nothing, nothing, nothing, nothing" from Obama on corporate tax cuts in five years, Grover Norquist tells CNBC.

  • July 24- Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma. Sales of Eliquis, which Bristol-Myers co-markets with Pfizer Inc, rose to $171 million.

  • July 24- Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but cost controls helped earnings beat forecasts.

  • Bristol 2Q net drops on lower drug sales, charges Thursday, 24 Jul 2014 | 7:42 AM ET

    NEW YORK— Bristol-Myers Squibb Co.' s exit from the diabetes business, plus higher taxes and research spending, combined to slash the drugmaker's second-quarter profit by 38 percent, but the company handily beat Wall Street's muted profit expectations.

  • These deals may suffer in US ‘inversion’ crackdown Thursday, 24 Jul 2014 | 6:40 AM ET

    President Barack Obama’s push to deter U.S. firms from buying foreign companies for tax purposes will make several deals less attractive.

  • Obama wants limits on US company mergers abroad Thursday, 24 Jul 2014 | 3:03 AM ET

    LOS ANGELES— Staking out a populist stand ahead of the midterm elections, President Barack Obama on Thursday demanded "economic patriotism" from U.S. corporations that use legal means to avoid U.S. taxes through overseas mergers. "I don't care if it's legal," Obama declared.

  • LONDON, July 23- GlaxoSmithKline cut its 2014 earnings outlook after sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.

  • UPDATE 2-GSK warns on profits as weak lung drug sales hit Wednesday, 23 Jul 2014 | 9:12 AM ET

    LONDON, July 23- GlaxoSmithKline cut its 2014 earnings outlook after sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.